<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thyromimetic agents that can treat <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> without adverse effects like <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> and <z:hpo ids='HP_0000939'>osteoporosis</z:hpo> are attractive options </plain></SENT>
<SENT sid="1" pm="."><plain>Initial experience with desssicated thyroid hormone extract and DT4 were disappointing </plain></SENT>
<SENT sid="2" pm="."><plain>Thyroid hormone has nuclear action with four receptor isoforms- TR α1, TRα2, TRβ1, TRβ2 </plain></SENT>
<SENT sid="3" pm="."><plain>TR α1 has predominant effects on CVS, TRβ2 acts mainly on the pituitary and TRβ1 has hepatoselective action and decrease cholesterol levels </plain></SENT>
<SENT sid="4" pm="."><plain>Eprotirome and Sobetirome are 2 thyromimetics that have selective TRβ1 activity </plain></SENT>
<SENT sid="5" pm="."><plain>They act in <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> by multiple mechanisms </plain></SENT>
<SENT sid="6" pm="."><plain>They are presumably safe on the pituitary- thyroid axis </plain></SENT>
</text></document>